$DNTH News

Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target

Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion

Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics to Participate in Three Investor Conferences During September

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128

HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results